Ono Pharma Seeks Japan Approval for OPDIVO Thyroid Cancer Treatment, June 12

Ono Pharmaceutical submitted a supplemental application in Japan on June 11 to expand OPDIVO’s approved use for unresectable anaplastic thyroid cancer. The application follows positive results from a phase 2 trial combining OPDIVO with Lenvima, which met its primary endpoint with a 47.6% objective response rate. This regulatory step matters to investors because it could unlock a new market segment for the immunotherapy in Japan’s healthcare system.

Trial Results Support the Application

The NAVIGATION study, conducted by Japan’s National Cancer Center Hospital East, tested OPDIVO combined with Lenvima in patients with unresectable anaplastic thyroid cancer. The trial achieved a 47.6% objective response rate, meeting the primary endpoint. Safety data showed adverse events were manageable with appropriate medical measures, supporting the drug combination’s clinical viability.

Rare Cancer with Poor Prognosis

Anaplastic thyroid cancer is a rare malignancy with an estimated 170 to 1,640 patients in Japan. The disease carries a poor prognosis and limited treatment options. Several drugs already have approval for this indication, but the OPDIVO plus Lenvima combination offers an additional therapeutic choice for Japanese patients facing this aggressive cancer type.

What Approval Could Mean

If Japan’s regulatory authority approves the supplemental application, OPDIVO would gain a new indication in a market where Ono Pharma submitted the filing on June 11. Approval would expand the drug’s addressable market and could strengthen Ono’s competitive position in oncology. The timeline for a regulatory decision remains unclear from the announcement.

Final Thoughts

Ono Pharma’s supplemental application for OPDIVO in anaplastic thyroid cancer is backed by solid trial data, but approval timing and market uptake remain uncertain. The rare cancer indication offers limited revenue upside compared to larger oncology markets.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.